Menu
Back to Archived Journals » Clinical Oncology in Adolescents and Young Adults » Volume 1
Urachal carcinoma with liver, lung, and brain metastases: benefit of a new combination chemotherapy (bevacizumab, 5-fluorouracil, irinotecan) – case report
Authors Geurs F, Dekoninck J, Demetter P, Deloecker R
Published 30 May 2011 Volume 2011:1 Pages 11—15
DOI https://doi.org/10.2147/COAYA.S18841
Review by Single anonymous peer review
Peer reviewer comments 3
J Dekoninck1, P Demetter2, Filip Geurs1, R De Loecker3
1Department of Medical Oncology, Regional Hospital Sint Maria, Halle, Belgium; 2Department of Pathology, Hopital Erasme – Université Libre de Bruxelles (ULB), Anderlecht, Belgium; 3Department of Laboratory, Regional Hospital Sint Maria, Halle, Belgium
Abstract: After failure of cisplatin-based chemotherapy for metastatic urachal carcinoma, a 16-year-old patient presents with diffuse liver-, lung-, and brain metastases. The K-ras mutation is present in the liver as well as in the primary resected specimen. The regimen was therefore changed to bevacizumab, 5-fluorouracil, and irinotecan. This led to a partial response which lasted 7 months.
Keywords: K-ras mutation, urachal cancer, adenocarcinoma
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.